Domantis
Latest round
- Series B
Last raised
- Dec 2005
Total raised
- $62M
Investors
- 5
About Domantis
Founded in 2000 in Waltham, Massachusetts, Domantis develops innovative biopharmaceutical solutions with a specialization in domain antibodies and glycosylation processes. In January 2007, the company was acquired by GlaxoSmithKline for approximately USD 454 mn, marking a significant milestone in its operations.Domantis Ltd. specializes in the development of domain antibodies (dAbs) and glycan-based therapeutics, which are critical in advancing therapeutic efficacy and biopharmaceutical applications. Their core product offerings focus on glycosylation processes, which significantly enhance protein stability, folding, and interactions, particularly in monoclonal antibodies. By leveraging advanced technologies such as glycan mapping and glycoengineering, the company aims to improve therapeutic outcomes in various disease treatment protocols. Domantis serves a diverse clientele, including biopharmaceutical companies and research institutions across North America, Europe, and Asia.Domantis Ltd. generates revenue through a B2B model, providing its specialized glycan-based therapeutics and domain antibodies to pharmaceutical and biotech companies engaged in drug development. Transactions typically occur through partnerships and licensing agreements, where clients procure specific products for their research and development needs. These agreements may entail upfront payments combined with royalties based on the sales performance of the resulting therapeutics. While specific pricing details for individual products are proprietary, the company’s flagship offerings, including its patented dAbs and glycoengineering solutions, are positioned to command premium pricing due to their innovative nature and the advanced technology involved in their development.Domantis plans to utilize the proceeds from its recent acquisition by GlaxoSmithKline, amounting to USD 454 mn, to further enhance its research and development capabilities. The company is focused on designing new products, particularly in the domain of glycan-based therapeutics, with a view to launch in the next few years. Additionally, there are strategic initiatives aimed at expanding into new geographic markets, particularly in Asia and Europe, by 2025, capitalizing on the growing demand for innovative therapies in those regions.
Who invested in Domantis
5 investors across 2 rounds
See all investors in Domantis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Domantis
Who invested in Domantis?
Domantis has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Domantis raised?
Domantis has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Domantis last raise money?
Domantis's most recent round on record is a Series B, in Dec 2005.
What does Domantis do?
Founded in 2000 in Waltham, Massachusetts, Domantis develops innovative biopharmaceutical solutions with a specialization in domain antibodies and glycosylation processes.
Where is Domantis headquartered?
Domantis is headquartered in Waltham, US.
Which VCs invest in companies like Domantis?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Domantis's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Domantis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.